secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001140361-25-006524
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio closes $575M 1.75% convertible notes due 2031; refinances Blue Owl secured debt
--------------------------------------------------------------------------------

- Issued $575M aggregate principal of 1.75% convertible senior notes due March 1, 2031.
- Net proceeds of ~$563M; used $48.3M to repurchase 1.4M shares at $34.35.
- Repaid and terminated Financing Agreement with Blue Owl, eliminating ~$51.5M annual interest.
- Notes are senior unsecured; conversion price ~$49.81 per share (45% premium).
- May not redeem before March 6, 2028; can redeem after if stock exceeds 130% of conversion price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125006524/0001140361-25-006524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125006524/ef20044715_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-006524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer